 | | - June 6th - Webinar - Open Forum Discussion on Oral Cancer
- Congrats to Dr. Ha
- Meet Ambassador Thomas Bennett
- Save the Date for our 2023 Survivorship Symposium
- "News & Shorts" - upcoming events, surveys, webinars and more
- Featured Clinic Trials
|
| |
|
|
|
| | Open Forum Discussion on Oral Cancer, Its Treatments & Side Effects Date: June 6th, 6-7 PM ET
Description: We are offering an open forum for all head and neck cancer patients, survivors, and caregivers to ask questions and converse with some of the US’s leading experts in oral oncology, oral oncology dentistry, and speech-language therapy. Be prepared to ask your specific questions to our expert panel. For more details visit our website | | | | |
| |
|
| | CONGRATULATIONS TO HNCA BOARD MEMBER, DR. HA
Join us in congratulating Patrick Ha, MD, for receiving the Excellence in Teaching for Clinical Faculty Award. Dr. Ha is a professor and the Chief of Head and Neck Oncologic Surgery at the Department of Otolaryngology and Head and Neck Surgery at the University of California, San Francisco (UCSF OHNS). Dr. Ha received multiple nominations from the Class of 2023 and is one of the five award winners in the Excellence in Teaching for Clinical Faculty category. "It's such a privilege to work with such talented medical students, and I'm honored to be recognized by them," said Dr. Ha. "Their engagement makes coming to work a true pleasure." Recipients of the annual award are nominated and selected by members of the graduating class of medical students. The awardees are selected for their work to advance the professional development of the graduating class. |
|
|
| | | Tom Bennett, born and raised in Westport, Connecticut....One day, in early July of 2015 while on a business trip, he noticed a lump on his neck while shaving. He figured he’d been exposed to some dust, and it was just another sinus infection. That’s when his cancer journey began. In July, once back in Connecticut, he scheduled a doctor’s appointment. His doctor did an examination, believing it also to be infection and prescribed antibiotics. This was the first miss by a doctor of his HPV-attributed throat cancer diagnosis. Tom then went to an infectious disease physician for four weeks and was yet to receive a proper diagnosis. He then underwent a CT scan, where the radiologist reported a “mass at base of tongue”. Protocol called for a visit to an ENT. “I remember that day clearly. The doctor didn’t diagnose me at that time, he just told me that I needed to see one of two doctors at Yale, and if I couldn’t get to see one of them within a week to call him. Well, that’s when the panic began to set in,” explained Tom. |
| |
|
| | PREVIOUS WEBINARS ARE ONLINE!
If you've missed (or want to re-watch) any of our previous webinars, don't forget they are all uploaded to our YouTube page! There's even a playlist for webinars so you can easily find them all. |
| |
|
| | |  | Join Imerman Angels for a broad overview and understanding of what clinical trials are, the benefits of joining one and some questions potential participants should consider. Participants should walk away feeling more confident about the role clinical trials play in our understanding of cancer, and the steps needed to research and enroll in an active trial. Find out more. |
|
|
 | The Rare Cancer Research Foundation, is hosting an upcoming webinar on Friday, May 19th at 3:30pm EST titled "Empowering Patients, Accelerating Research, Together with Pattern.org".
This free event is designed to put patients at the forefront, providing valuable information on how to contribute to rare cancer research through Pattern.org.
Find out more |
|
|
|  | The University of Washington SPEAC Lab is inviting individuals who with select communication-related diagnoses to answer survey questions about their communication experiences. Your participation will help healthcare providers support others with communication disorders and the important people in their lives to stay connected through communication. Each participant will be mailed a $25 check upon survey completion. Find out more |
|
|
 | Dr. Bonnie Martin-Harris and her team are studying a new swallowing therapy to improve eating, drinking, health, and quality-of-life of individuals who were recently treated for head and neck cancer.
Therapy will be conducted remotely. Four visits will be required to Northwestern Memorial Hospital (Chicago) to examine swallowing and breathing function across 5 months.
Download a Word doc with more info |
|
|
| | |
|
| | FEATURED CLINICAL TRIALS *Sponsor Content | Learn HNCA's stance on corporate support below. |
| | |
|
|
|
| |  | Earlier this year, 7 inspiring advocates got together to discuss the similarities and differences of their personal experiences with head and neck cancer (HNC). Get inspired by their stories through a unique Made of More video series launching next month on YouTube. Made of More |
|
|
|
|
|  - SPONSORED ARTICLE
Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox™ platform, is excited to share that the new data on safety and efficacy from a phase 1b/2 study of Alluminox treatment (photoimmunotherapy) using ASP-1929 in combination with anti-PD-1 therapy in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) will be presented at this year’s American Head and Neck Society (AHNS) 11th International Conference on Head and Neck Cancer. Rakuten Medical will also have a booth display in the exhibit hall. In addition, several presentations involving Alluminox treatment (photoimmunotherapy) have also been selected for presentation at AHNS 2023. Read more on https://rakuten-med.com/us/news/press-releases/2023/05/12/7709/. The Alluminox™ platform is an investigational technology platform based on a cancer therapy called photoimmunotherapy, which, in pre-clinical studies, have been shown to induce rapid and selective cell killing and tumor necrosis. The company’s first drug developed on the Alluminox™ platform, ASP-1929, together with a medical device used in combination with the drug, has received marketing approval under the Conditional Early Approval System in Japan for unresectable locally advanced or recurrent head and neck cancer, and is currently under investigation in a global Phase 3 clinical trial for recurrent head and neck cancer in several countries including the U.S. The Phase 3, randomized, double-arm, open-label, controlled trial of Alluminox treatment using ASP-1929, which is currently enrolling patients (ASP-1929-301/ClinicalTrials.gov Identifier: NCT03769506), will evaluate the efficacy, safety and tolerability of ASP-1929 photoimmunotherapy in patients with locoregional, recurrent HNSCC who have previously failed or progressed on or after at least two lines of therapy, of which at least one line must be systemic therapy. The dual-primary endpoints of the study are progression-free survival and overall survival, and key secondary endpoint is objective response rate. * Rakuten Medical’s therapies based on Alluminox™ platform are investigational outside of Japan. For more information about Rakuten Medical, visit www.rakuten-med.com. |
| | | | | Thank You to our Corporate Partners |
|  | | | |
|
| *Statement on Sponsor Content and Corporate Support: The information published on this website and in our materials is intended to educate you about Oral, Head and Neck Cancer. The content is not intended to take the place of a discussion with a qualified physician who is familiar with your medical situation. It is important to remember that each individual is different, and the reasons for—and outcomes of—any treatment plan depends on the patient's individual condition. If you have questions or concerns after reading any information on this website or in our materials, you should discuss them openly and honestly with your physician. Any products and manufacturers included on this site are presented for informational purposes only and do not constitute product approval or endorsement by HNCA. The content provided by HNCA is in no way intended to be a substitute for medical consultation with a qualified professional. HNCA encourages those using its resources to be careful when evaluating medical information or products. If you are unsure about your medical condition, consult a physician. Funding from our corporate partners supports HNCA’s programs and educational initiatives, and HNCA maintains independence in its design of programs, content, and initiatives. |
| | Head and Neck Cancer Alliance
PO BOX 21688 | Charleston, South Carolina 29413
866-792-4622 | info@headandneck.org |
| | Be sure to add our email address to your address book or safe senders list so our emails get to your inbox. Having trouble viewing this email? View it in your web browser |
|
|
| |
|
|
